Evidence map›Paper›PMID 34910129›Full record

ArticleThe British journal of surgery2022

Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.

Saqib Rahman, Betsan Thomas, Nick Maynard, Min Hae Park, Muhammad Wahedally, Nigel Trudgill, Tom Crosby, David A Cromwell, Tim J Underwood

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Saqib RahmanSchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID 0000-0001-9489-0021
Betsan ThomasDepartment of Oncology, Velindre University NHS Trust, Cardiff, UK.
Nick MaynardDepartment of Upper Gastrointestinal Surgery, Oxford University Hospitals NHS Trust, Oxford, UK.
Min Hae ParkClinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
Muhammad WahedallyClinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
Nigel TrudgillDepartment of Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.
Tom CrosbyDepartment of Oncology, Velindre University NHS Trust, Cardiff, UK.
David A CromwellClinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
Tim J UnderwoodSchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Royal College of Surgeons of England · GBVelindre NHS Trust · GBOxford University Hospitals NHS Trust · GBSandwell & West Birmingham Hospitals NHS Trust · GBUniversity of Southampton · GB

Funding

Cancer Research UK 23924
6 · The paper itself

Abstract

backgroundPerioperative chemotherapy is widely used in the treatment of oesophagogastric adenocarcinoma (OGAC) with a substantial survival benefit over surgery alone. However, the postoperative part of these regimens is given in less than half of patients, reflecting uncertainty among clinicians about its benefit and poor postoperative patient fitness. This study estimated the effect of postoperative chemotherapy after surgery for OGAC using a large population-based data set.

methodsPatients with adenocarcinoma of the oesophagus, gastro-oesophageal junction or stomach diagnosed between 2012 and 2018, who underwent preoperative chemotherapy followed by surgery, were identified from a national-level audit in England and Wales. Postoperative therapy was defined as the receipt of systemic chemotherapy within 90 days of surgery. The effectiveness of postoperative chemotherapy compared with observation was estimated using inverse propensity treatment weighting.

resultsPostoperative chemotherapy was given to 1593 of 4139 patients (38.5 per cent) included in the study. Almost all patients received platinum-based triplet regimens (4004 patients, 96.7 per cent), with FLOT used in 3.3 per cent. Patients who received postoperative chemotherapy were younger, with a lower ASA grade, and were less likely to have surgical complications, with similar tumour characteristics. After weighting, the median survival time after postoperative chemotherapy was 62.7 months compared with 50.4 months without chemotherapy (hazard ratio 0.84, 95 per cent c.i. 0.77 to 0.94; P = 0.001).

conclusionThis study has shown that postoperative chemotherapy improves overall survival in patients with OGAC treated with preoperative chemotherapy and surgery.

Indexed as

Chemotherapy, AdjuvantEsophagogastric JunctionAdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantEsophageal NeoplasmsFemaleFollow-Up StudiesHumansMaleMiddle AgedPostoperative CarePreoperative CareRetrospective StudiesStomach Neoplasms

Identifiers

PMID34910129
PMCPMC10364695
OpenAlexW4200334513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.